 | • レポートコード：MRC2203A079 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のがん診断市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断種類別（画像診断検査、生検・細胞診検査、腫瘍バイオマーカー、その他）分析、用途別（乳がん、肺がん、子宮頸がん、腎臓がん、肝臓がん）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のがん診断市場規模：診断種類別（画像診断検査、生検・細胞診検査、腫瘍バイオマーカー、その他） ・世界のがん診断市場規模：用途別（乳がん、肺がん、子宮頸がん、腎臓がん、肝臓がん） ・世界のがん診断市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbott Laboratories Inc.、F. Hoffmann-La Roche Ltd、Siemens Healthineers、…） ・市場機会・将来傾向 |
The cancer diagnostics market is expected to register a CAGR of 9.7% during the forecast period.
Due to the outbreak of the COVID-19, the market observed a significant setback in terms of growth. As the COVID-19 cases rose, the healthcare system shifted its focus in curbing the disease, resulting in the delay of diagnosis and treatment of other chronic conditions like cancer. Thus, a negative impact is expected on the cancer diagnostics market due to the pandemic scenario. However, in the coming years, a significant rise is expected in the diagnostic procedures related to cancer.
An increase in the number of cancer cases and the rise in the geriatric population are the major factors contributing to the growth of the cancer diagnostics market globally. According to the GLOBOCAN, 2020, about 19.3 million new cancer cases were reported worldwide, and this number is expected to reach 30.2 million new cases in the year 2040. Globally, about one out of 6 deaths occurs due to cancer, as per the World Health Organization factsheet. About 70% of deaths from cancer occur in low- and middle-income countries.
As per the World Ageing report 2019, the geriatric population (aged 65 years and above) was reported to be around 702.9 million, and this number is expected to increase to 1,548.9 million by the year 2050. Furthermore, the increase in the emergence of new technologies, like biomarkers and point of care testing, the inclination toward advanced less-painful and way more efficient tests from conventional tests, improved healthcare expenditure, growing awareness, and increased government support are factors boosting the growth of the cancer diagnostics market globally.
However, stringent regulatory framework, lack of universal health coverage, and expensive diagnostic procedures are the few factors restraining the growth of the cancer diagnostics market globally.
Key Market Trends
The Diagnostic Imaging Tests Segment is Expected to Hold a Major Market Share in the Cancer Diagnostics Market
The most commonly used screening test for cancer is diagnostic imaging tests. The different kinds of imaging techniques for cancer detection, like imaging (radiology) tests for cancer, CT scans, MRI, nuclear medicine scans, ultrasound, mammograms, X-rays, and other radiographic tests, are considered the most reliable ones.
However, screening, case identification, and referral in symptomatic cancer diagnosis were affected by the COVID-19 pandemic. Even the management and follow-up of cancer patients were affected by the pandemic. For instance, in 2020, the Netherlands Cancer Registry experienced a 40% decline in weekly cancer incidence. The United Kingdom experienced a 75% decline in referrals for suspected cancer since the onset of COVID-19.
Mammograms are the most widely used tests to diagnose cancers. Mammography is the gold standard technique used to screen breast cancer. Governments and other healthcare organizations worldwide are taking initiatives to provide women between 50 and 75 years access to mammography screening. In June 2019, Fujifilm Medical Systems U.S.A. announced a new breast cancer screening awareness campaign focused on early detection of the disease in the United States. The ‘Aspire to Be Fearless’ campaign involves a mobile mammography vehicle traveling throughout the United States to spread Fujifilm’s message. The vehicle includes a waiting room, dressing room, and the latest breast imaging solutions from Fujifilm.
Furthermore, the development of new technologically advanced products for cancer diagnosis is expected to support the market growth. In January 2020, Allengers launched the ACUTOM-32 CT scanner in India, collaborating with Canon Medical Systems Corporation (CMSC). Thus, the segment is expected to show growth in the near future due to the above-mentioned factors.
North America is Anticipated to Observe a Significant Growth in the Global Cancer Diagnostics Market
North America is expected to majorly contribute to the cancer diagnostics market growth. With the emergence of COVID-19, the region also observed a negative impact on the market studied. According to the Union for International Cancer Controls (UICC), there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. According to its survey analysis, newly diagnosed metastatic non-small cell lung cancer patient volumes declined just over 30% from February of 2020 to March 2020. Declines were also observed in colorectal cancer (14% ), acute myeloid leukemia (14%), breast cancer (8.4% ), and ovarian cancer (8.6%). Such instances indicate a decline in the diagnosis rate of cancer during the pandemic era.
The key factors contributing to the market growth are the rising burden of cancer, the development of new products, and the rising awareness of the disease.
Furthermore, as per the data provided by GLOBOCAN, 2020, about 2,281,658 new cancer cases were reported, with a 5-year prevalence of about 8,432,938 in the same year. The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.
In January 2020, the American Cancer Society and Pfizer approved grants totaling more than USD 2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis. Thus, with these factors, the market is expected to flourish in the region.
Competitive Landscape
The cancer diagnostics market is highly fragmented, with the presence of a large number of local and international players. Key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientifica Inc., and Qiagen.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Ease of Cancer Diagnosis
4.2.2 Increasing Burden of Cancer Globally
4.2.3 Emergence of New Technologies such as Biomarkers and Point of Care Testing
4.3 Market Restraints
4.3.1 Limited Use in the Emerging Markets
4.3.2 Expensive Diagnostic Procedures
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Diagnostic Type
5.1.1 Diagnostic Imaging Tests
5.1.2 Biopsy and Cytology Tests
5.1.3 Tumor Biomarkers
5.1.4 Other Diagnostic Types
5.2 By Application
5.2.1 Breast Cancer
5.2.2 Lung Cancer
5.2.3 Cervical Cancer
5.2.4 Kidney Cancer
5.2.5 Liver Cancer
5.2.6 Pancreatic Cancer
5.2.7 Ovarian Cancer
5.2.8 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Siemens Healthineers
6.1.4 Thermo Fisher Scientific Inc.
6.1.5 GE Healthcare
6.1.6 Hologic Inc.
6.1.7 Illumina Inc.
6.1.8 Bio-Rad Laboratories Inc.
6.1.9 Agilent Technologies Inc.
6.1.10 Biomeriuex SA
6.1.11 Cancer Diagnostic Inc.
6.1.12 Myriad Genetic Laboratories Inc.
6.1.13 Qiagen
6.1.14 MolecularMD Corporation
6.1.15 Dako North America Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS